[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psma-positive-tumors-or-tumor-tissues\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psma-positive-tumors-or-tumor-tissues":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100395465","phase-1-psma-specific-car-t-cell-therapy-100395465",false,"NCT04429451","PSMA-specific CAR-T Cell Therapy","Phase I\u002FII Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies","Inclusion Criteria:\n\n1. Patients with tumors have received standard first-line therapy and have been judged to be non-respectable, metastatic, progressive or recurrent.\n2. The expression status of PSMA antigens in the tumor tissue will be determined for eligibility. Positive expression is defined by PMSA antibody staining results based on immunohistochemistry or flow cytometry analyses.\n3. Body weight greater than or equal to 10 kg.\n4. Age: ≥1 year and ≤ 75 years of age at the time of enrollment.\n5. Life expectancy: at least 8 weeks.\n6. Prior Therapy:\n\n   There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less.\n7. Participant must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection.\n8. At least 7 days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic non-myelosuppressive regimen.\n9. At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody.\n10. At least 1 week since any radiation therapy at the time of study entry.\n11. Karnofsky\u002Fjansky score of 60% or greater.\n12. Cardiac function: Left ventricular ejection fraction greater than or equal to 40\u002F55 percent.\n13. Pulse Ox greater than or equal to 90% on room air.\n14. Liver function: defined as alanine transaminase (ALT) \\\u003C3x upper limit of normal (ULN), aspartate aminotransferase (AST) \\\u003C3x ULN; serum bilirubin and alkaline phosphatase \\\u003C2x ULN.\n15. Renal function: Patients must have serum creatinine less than 3 times upper limit of normal.\n16. Marrow function: White blood cell count ≥1000\u002Ful, Absolute neutrophil count ≥500\u002Ful, Absolute lymphocyte count ≥500\u002Ful, Platelet count ≥25,000\u002Ful (not achieved by transfusion).\n17. Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease does not have hematologic toxicity.\n18. For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent.\n\nExclusion Criteria:\n\n1. Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, or greater than grade 2 hematologic toxicity.\n2. Untreatable central nervous system (CNS) metastasis: Patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible.\n3. Previous treatment with other genetically engineered PSMA-specific CAR T cells or antibody therapy.\n4. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.\n5. Patients who require systemic corticosteroid or other immunosuppressive therapy.\n6. Evidence of tumor potentially causing airway obstruction.\n7. Inability to comply with protocol requirements.\n8. Insufficient CAR T cells availability.","ALL","1 Year","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.",[28],"PSMA Positive Tumors or Tumor Tissues",[30,31,32,33,34,35],"chimeric antigen receptor","adoptive T cell transfer","PSMA","Prostate cancer","Tumor microenvironment","CAR","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":40},"2026-06-01",{"date":44,"type":21},"2030-12-31",{"name":46,"class":47},"Shenzhen Geno-Immune Medical Institute","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100599827","psma-pet-for-treatment-response-evaluation-of-systemic-therapies-in-prostate-cancer-pelican-100599827","NCT07089550","PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN), an Italian Multicenter Study","PELICAN","Inclusion Criteria:\n\n* Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma);\n* Patients undergoing PSMA PET for pre-treatment disease staging;\n* Candidates to receive one or more of the following systemic therapies, in combination or alone: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA;\n* Provision of signed informed consent for study participation and data handling.\n\nExclusion Criteria:\n\n* Inability to remain supine and still for the PET\u002FCT image acquisition;\n* Prostate cancer with a known significant neuroendocrine component;\n* Presence of another concurrent malignancy, with the exception of non-melanoma skin cancer.","MALE","18 Years",{"count":60,"type":21},1300,"2 Years","OBSERVATIONAL","This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.\n\nThe primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population.\n\nThis study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.",[28,65],"Prostate Cancer Metastatic",[67,68,69],"PSMA PET\u002FCT","mCRPC","mHSPC","2026-02-19",{"date":72,"type":40},"2026-02-20",{"date":74,"type":40},"2025-04-02",{"date":76,"type":21},"2034-04-26",{"name":78,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",4]